MHC ligands as potential therapeutics in the treatment of autoimmune and allergic diseases

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.7, Iss.1, 1997-01, pp. : 29-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 5, Iss. 3, 2005-09 ,pp. : 315-322

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases

Current Pharmaceutical Design, Vol. 16, Iss. 9, 2010-03 ,pp. : 1136-1142

Bentham Science Publishers

Access to resources Recommend Favorite

RNA Interference: New Therapeutics in Allergic Diseases

Current Gene Therapy, Vol. 8, Iss. 4, 2008-08 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 11, 2015-01 ,pp. : 1002-1011

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic Immunomodulation of Autoimmune Disease Using MHC-Derived Recombinant TCR Ligands

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 2, 2005-04 ,pp. : 185-193

Bentham Science Publishers

Access to resources Recommend Favorite